Načítá se...
Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients
Addition of brentuximab vedotin, a CD30-targeted antibody–drug conjugate, and the programmed death 1 (PD-1) inhibitors nivolumab and pembrolizumab to the armamentarium for transplant-ineligible relapsed/refractory classical Hodgkin lymphoma has resulted in improved outcomes, including the potential...
Uloženo v:
| Vydáno v: | Blood |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society of Hematology
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6536701/ https://ncbi.nlm.nih.gov/pubmed/29500171 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-09-772681 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|